{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:29:01Z","timestamp":1793741341802,"version":"4.6.1"},"reference-count":188,"publisher":"Bentham Science Publishers Ltd.","issue":"31","funder":[{"DOI":"10.13039\/501100011828","name":"Innovation Project of Guangxi Graduate Education","doi-asserted-by":"publisher","award":["YCBZ2019044"],"award-info":[{"award-number":["YCBZ2019044"]}],"id":[{"id":"10.13039\/501100011828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011823","name":"Project of Educational Commission of GuangXi Province of China","doi-asserted-by":"publisher","award":["02601217033C"],"award-info":[{"award-number":["02601217033C"]}],"id":[{"id":"10.13039\/501100011823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province of China","doi-asserted-by":"publisher","award":["2018GXNSFBA050068"],"award-info":[{"award-number":["2018GXNSFBA050068"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011828","name":"Guangxi Medical and Health Appropriate Technology Research and Development Project","doi-asserted-by":"publisher","award":["S201517"],"award-info":[{"award-number":["S201517"]}],"id":[{"id":"10.13039\/501100011828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009329","name":"Programs for Science and Technology Development of Guangxi Province of China","doi-asserted-by":"publisher","award":["1598011-2"],"award-info":[{"award-number":["1598011-2"]}],"id":[{"id":"10.13039\/501100009329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,1,3]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Cilostazol is a unique platelet inhibitor that has been used clinically for more than 20 years. As a phosphodiesterase type III inhibitor, cilostazol is capable of reversible inhibition of platelet aggregation and vasodilation, has antiproliferative effects, and is widely used in the treatment of peripheral arterial disease, cerebrovascular disease, percutaneous coronary intervention, etc. This article briefly reviews the pharmacological mechanisms and clinical application of cilostazol.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568026619666191122123855","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T16:12:39Z","timestamp":1574698359000},"page":"2919-2936","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Progress in the Mechanism and Clinical Application of Cilostazol"],"prefix":"10.2174","volume":"19","author":[{"given":"Huilei","family":"Zheng","sequence":"first","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Gong","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxian","family":"Mai","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Qiu","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidai","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhou","family":"Su","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoqi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Computer Science and Engineering, University of Bridgeport,126 Park Ave, BRIDGEPORT, CT 06604, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention,Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/14656566.2018.1515199","volume":"19","author":"Noma K.","year":"2018","unstructured":"Noma K.; Higashi Y.; Cilostazol for treatment of cerebral infarction. Expert Opin Pharmacother 2018,19(15),1719-1726","journal-title":"Expert Opin Pharmacother"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.nano.2018.07.010","volume":"14","author":"Kan C.D.","year":"2018","unstructured":"Kan C.D.; Wang J.N.; Li W.P.; Lin S.H.; Chen W.L.; Hsu Y.P.; Yeh C.S.; Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease. Nanomedicine (Lond) 2018,14(7),2205-2213","journal-title":"Nanomedicine (Lond)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12882-018-0854-0","volume":"19","author":"Shima H.","year":"2018","unstructured":"Shima H.; Tashiro M.; Yamada S.; Matsuura M.; Okada K.; Doi T.; Minakuchi J.; Kawashima S.; Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report. BMC Nephrol 2018,19(1),52","journal-title":"BMC Nephrol"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010512.pub2","volume":"3","author":"Fakhry F.","year":"2018","unstructured":"Fakhry F.; Fokkenrood H.J.; Spronk S.; Teijink J.A.; Rouwet E.V.; Hunink M.G.M.; Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev 2018,3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.pcad.2018.03.007","volume":"60","author":"McDermott M.M.","year":"2018","unstructured":"McDermott M.M.; Medical management of functional impairment in peripheral artery disease: A review. Prog Cardiovasc Dis 2018,60(6),586-592","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1463-1326.2002.0040s2s14.x","volume":"4","author":"Schr\u00f6r K.","year":"2002","unstructured":"Schr\u00f6r K.; The pharmacology of cilostazol. Diabetes Obes Metab 2002,4(Suppl. 2),S14-S19","journal-title":"Diabetes Obes Metab"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0049-3848(00)00415-1","volume":"101","author":"Kariyazono H.","year":"2001","unstructured":"Kariyazono H.; Nakamura K.; Shinkawa T.; Yamaguchi T.; Sakata R.; Yamada K.; Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 2001,101(6),445-453","journal-title":"Thromb Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2174\/1389557517666170927141323","volume":"18","author":"Meiring L.","year":"2018","unstructured":"Meiring L.; Petzer J.P.; Petzer A.; A review of the pharmacological properties of 3,4-dihydro-2(1H)- quinolinones. Mini Rev Med Chem 2018,18(10),828-836","journal-title":"Mini Rev Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2174\/1573406411666141229162834","volume":"11","author":"Chou K.C.","year":"2015","unstructured":"Chou K.C.; Impacts of bioinformatics to medicinal chemistry. Med Chem 2015,11(3),218-234","journal-title":"Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature17656","volume":"533","author":"Oxenoid K.","year":"2016","unstructured":"Oxenoid K.; Dong Y.; Cao C.; Cui T.; Sancak Y.; Markhard A.L.; Grabarek Z.; Kong L.; Liu Z.; Ouyang B.; Cong Y.; Mootha V.K.; Chou J.J.; Architecture of the mitochondrial calcium uniporter. Nature 2016,533(7602),269-273","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature10257","volume":"476","author":"Berardi M.J.","year":"2011","unstructured":"Berardi M.J.; Shih W.M.; Harrison S.C.; Chou J.J.; Mitochondrial uncoupling protein 2 structure determined by NMR molecular fragment searching. Nature 2011,476(7358),109-113","journal-title":"Nature"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.aaf7066","volume":"353","author":"Dev J.","year":"2016","unstructured":"Dev J.; Park D.; Fu Q.; Chen J.; Ha H.J.; Ghantous F.; Herrmann T.; Chang W.; Liu Z.; Frey G.; Seaman M.S.; Chen B.; Chou J.J.; Structural basis for membrane anchoring of HIV-1 envelope spike. Science 2016,353(6295),172-175","journal-title":"Science"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06531","volume":"451","author":"Schnell J.R.","year":"2008","unstructured":"Schnell J.R.; Chou J.J.; Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008,451(7178),591-595","journal-title":"Nature"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(00)81417-8","volume":"94","author":"Chou J.J.","year":"1998","unstructured":"Chou J.J.; Matsuo H.; Duan H.; Wagner G.; Solution structure of the RAIDD CARD and model for CARD\/CARD interaction in caspase-2 and caspase-9 recruitment. Cell 1998,94(2),171-180","journal-title":"Cell"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0014-5793(97)01246-5","volume":"419","author":"Chou K.C.","year":"1997","unstructured":"Chou K.C.; Jones D.; Heinrikson R.L.; Prediction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett 1997,419(1),49-54","journal-title":"FEBS Lett"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bbrc.2004.05.016","volume":"319","author":"Chou K.C.","year":"2004","unstructured":"Chou K.C.; Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem Biophys Res Commun 2004,319(2),433-438","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1021\/pr050145a","volume":"4","author":"Chou K.C.","year":"2005","unstructured":"Chou K.C.; Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J Proteome Res 2005,4(5),1681-1686","journal-title":"J Proteome Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbrc.2005.03.123","volume":"331","author":"Chou K.C.","year":"2005","unstructured":"Chou K.C.; Modeling the tertiary structure of human cathepsin-E. Biochem Biophys Res Commun 2005,331(1),56-60","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/pr050135+","volume":"4","author":"Chou K.C.","year":"2005","unstructured":"Chou K.C.; Insights from modeling the 3D structure of DNA-CBF3b complex. J Proteome Res 2005,4(5),1657-1660","journal-title":"J Proteome Res"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038546","volume":"7","author":"Ma Y.","year":"2012","unstructured":"Ma Y.; Wang S.Q.; Xu W.R.; Wang R.L.; Chou K.C.; Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One 2012,7(6)","journal-title":"PLoS One"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbrc.2009.06.016","volume":"386","author":"Wang S.Q.","year":"2009","unstructured":"Wang S.Q.; Du Q.S.; Huang R.B.; Zhang D.W.; Chou K.C.; Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem Biophys Res Commun 2009,386(3),432-436","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028111","volume":"6","author":"Li X.B.","year":"2011","unstructured":"Li X.B.; Wang S.Q.; Xu W.R.; Wang R.L.; Chou K.C.; Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method. PLoS One 2011,6(11)","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-5793(00)01333-8","volume":"470","author":"Chou K.C.","year":"2000","unstructured":"Chou K.C.; Tomasselli A.G.; Heinrikson R.L.; Prediction of the tertiary structure of a caspase-9\/inhibitor complex. FEBS Lett 2000,470(3),249-256","journal-title":"FEBS Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.bbrc.2006.12.235","volume":"354","author":"Wang S.Q.","year":"2007","unstructured":"Wang S.Q.; Du Q.S.; Chou K.C.; Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun 2007,354(3),634-640","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtbi.2015.04.011","volume":"377","author":"Jia J.","year":"2015","unstructured":"Jia J.; Liu Z.; Xiao X.; Liu B.; Chou K.C.; iPPI-Esml: An ensemble classifier for identifying the interactions of proteins by incorporating their physicochemical properties and wavelet transforms into PseAAC. J Theor Biol 2015,377,47-56","journal-title":"J Theor Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ab.2014.12.009","volume":"474","author":"Liu Z.","year":"2015","unstructured":"Liu Z.; Xiao X.; Qiu W.R.; Chou K.C.; iDNA-Methyl: identifying DNA methylation sites via pseudo trinucleotide composition. Anal Biochem 2015,474,69-77","journal-title":"Anal Biochem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12961","DOI":"10.1093\/nar\/gku1019","volume":"42","author":"Lin H.","year":"2014","unstructured":"Lin H.; Deng E.Z.; Ding H.; Chen W.; Chou K.C.; iPro54-PseKNC: a sequence-based predictor for identifying sigma-54 promoters in prokaryote with pseudo k-tuple nucleotide composition. Nucleic Acids Res 2014,42(21),12961-12972","journal-title":"Nucleic Acids Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/prot.1035","volume":"43","author":"Chou K.C.","year":"2001","unstructured":"Chou K.C.; Prediction of protein cellular attributes using pseudo-amino acid composition. Proteins 2001,43(3),246-255","journal-title":"Proteins"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055844","volume":"8","author":"Xu Y.","year":"2013","unstructured":"Xu Y.; Ding J.; Wu L.Y.; Chou K.C.; iSNO-PseAAC: predict cysteine S-nitrosylation sites in proteins by incorporating position specific amino acid propensity into pseudo amino acid composition. PLoS One 2013,8(2)","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/07391102.2014.998710","volume":"33","author":"Xiao X.","year":"2015","unstructured":"Xiao X.; Min J.L.; Lin W.Z.; Liu Z.; Cheng X.; Chou K.C.; iDrug-Target: predicting the interactions between drug compounds and target proteins in cellular networking via benchmark dataset optimization approach. J Biomol Struct Dyn 2015,33(10),2221-2233","journal-title":"J Biomol Struct Dyn"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ab.2014.04.001","volume":"456","author":"Chen W.","year":"2014","unstructured":"Chen W.; Lei T.Y.; Jin D.C.; Lin H.; Chou K.C.; PseKNC: a flexible web server for generating pseudo K-tuple nucleotide composition. Anal Biochem 2014,456,53-60","journal-title":"Anal Biochem"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/701317","volume":"2013","author":"Min J.L.","year":"2013","unstructured":"Min J.L.; Xiao X.; Chou K.C.; iEzy-drug: a web server for identifying the interaction between enzymes and drugs in cellular networking. BioMed Res Int 2013,2013","journal-title":"BioMed Res Int"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072234","volume":"8","author":"Xiao X.","year":"2013","unstructured":"Xiao X.; Min J.L.; Wang P.; Chou K.C.; iGPCR-drug: a web server for predicting interaction between GPCRs and drugs in cellular networking. PLoS One 2013,8(8)","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtbi.2013.08.013","volume":"337","author":"Xiao X.","year":"2013","unstructured":"Xiao X.; Min J.L.; Wang P.; Chou K.C.; iCDI-PseFpt: identify the channel-drug interaction in cellular networking with PseAAC and molecular fingerprints. J Theor Biol 2013,337,71-79","journal-title":"J Theor Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2174\/138920010791514261","volume":"11","author":"Chou K.C.","year":"2010","unstructured":"Chou K.C.; Graphic rule for drug metabolism systems. Curr Drug Metab 2010,11(4),369-378","journal-title":"Curr Drug Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2174\/15680266113139990113","volume":"13","author":"Xiao X.","year":"2013","unstructured":"Xiao X.; Lin W.Z.; Chou K.C.; Recent advances in predicting protein classification and their applications to drug development. Curr Top Med Chem 2013,13(14),1622-1635","journal-title":"Curr Top Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.2174\/15680266113139990121","volume":"13","author":"Xiao X.","year":"2013","unstructured":"Xiao X.; Min J.L.; Wang P.; Chou K.C.; Predict drug-protein interaction in cellular networking. Curr Top Med Chem 2013,13(14),1707-1712","journal-title":"Curr Top Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtbi.2011.06.006","volume":"284","author":"Zhou G.P.","year":"2011","unstructured":"Zhou G.P.; The disposition of the LZCC protein residues in wenxiang diagram provides new insights into the protein-protein interaction mechanism. J Theor Biol 2011,284(1),142-148","journal-title":"J Theor Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/(SICI)1097-0134(199705)28:1<99:AID-PROT10>3.0.CO;2-C","volume":"28","author":"Chou K.C.","year":"1997","unstructured":"Chou K.C.; Zhang C.T.; Maggiora G.M.; Disposition of amphiphilic helices in heteropolar environments. Proteins 1997,28(1),99-108","journal-title":"Proteins"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/minf.201300084","volume":"32","author":"Liu B.","year":"2013","unstructured":"Liu B.; Wang X.; Zou Q.; Dong Q.; Chen Q.; Protein remote homology detection by combining Chou\u2019s pseudo amino acid composition and profile-based protein representation. Mol Inform 2013,32(9-10),775-782","journal-title":"Mol Inform"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/bioinformatics\/btt709","volume":"30","author":"Liu B.","year":"2014","unstructured":"Liu B.; Zhang D.; Xu R.; Xu J.; Wang X.; Chen Q.; Dong Q.; Chou K.C.; Combining evolutionary information extracted from frequency profiles with sequence-based kernels for protein remote homology detection. Bioinformatics 2014,30(4),472-479","journal-title":"Bioinformatics"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018258","volume":"6","author":"Chou K.C.","year":"2011","unstructured":"Chou K.C.; Wu Z.C.; Xiao X.; iLoc-Euk: a multi-label classifier for predicting the subcellular localization of singleplex and multiplex eukaryotic proteins. PLoS One 2011,6(3)","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1039\/c3mb25466f","volume":"9","author":"Lin W.Z.","year":"2013","unstructured":"Lin W.Z.; Fang J.A.; Xiao X.; Chou K.C.; iLoc-Animal: a multi-label learning classifier for predicting subcellular localization of animal proteins. Mol Biosyst 2013,9(4),634-644","journal-title":"Mol Biosyst"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023505","volume":"6","author":"Wang P.","year":"2011","unstructured":"Wang P.; Xiao X.; Chou K.C.; NR-2L: a two-level predictor for identifying nuclear receptor subfamilies based on sequence-derived features. PLoS One 2011,6(8)","journal-title":"PLoS One"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1039\/c1mb05232b","volume":"7","author":"Wu Z.C.","year":"2011","unstructured":"Wu Z.C.; Xiao X.; Chou K.C.; iLoc-Plant: a multi-label classifier for predicting the subcellular localization of plant proteins with both single and multiple sites. Mol Biosyst 2011,7(12),3287-3297","journal-title":"Mol Biosyst"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/092986612798472839","volume":"19","author":"Wu Z.C.","year":"2012","unstructured":"Wu Z.C.; Xiao X.; Chou K.C.; iLoc-Gpos: a multi-layer classifier for predicting the subcellular localization of singleplex and multiplex Gram-positive bacterial proteins. Protein Pept Lett 2012,19(1),4-14","journal-title":"Protein Pept Lett"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jtbi.2011.06.005","volume":"284","author":"Xiao X.","year":"2011","unstructured":"Xiao X.; Wu Z.C.; Chou K.C.; iLoc-Virus: a multi-label learning classifier for identifying the subcellular localization of virus proteins with both single and multiple sites. J Theor Biol 2011,284(1),42-51","journal-title":"J Theor Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1039\/C1MB05420A","volume":"8","author":"Chou K.C.","year":"2012","unstructured":"Chou K.C.; Wu Z.C.; Xiao X.; iLoc-Hum: using the accumulation-label scale to predict subcellular locations of human proteins with both single and multiple sites. Mol Biosyst 2012,8(2),629-641","journal-title":"Mol Biosyst"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ab.2013.01.019","volume":"436","author":"Xiao X.","year":"2013","unstructured":"Xiao X.; Wang P.; Lin W.Z.; Jia J.H.; Chou K.C.; iAMP-2L: a two-level multi-label classifier for identifying antimicrobial peptides and their functional types. Anal Biochem 2013,436(2),168-177","journal-title":"Anal Biochem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1039\/c3mb25555g","volume":"9","author":"Chou K.C.","year":"2013","unstructured":"Chou K.C.; Some remarks on predicting multi-label attributes in molecular biosystems. Mol Biosyst 2013,9(6),1092-1100","journal-title":"Mol Biosyst"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3762\/bjnano.9.126","volume":"9","author":"Matus M.F.","year":"2018","unstructured":"Matus M.F.; Ludue\u00f1a M.; Vilos C.; Palomo I.; Mariscal M.M.; Atomic-level characterization and cilostazol affinity of poly(lactic acid) nanoparticles conjugated with differentially charged hydrophilic molecules. Beilstein J Nanotechnol 2018,9,1328-1338","journal-title":"Beilstein J Nanotechnol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejpb.2010.06.003","volume":"76","author":"Willmann S.","year":"2010","unstructured":"Willmann S.; Thelen K.; Becker C.; Dressman J.B.; Lippert J.; Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 2010,76(1),83-94","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jcis.2018.10.026","volume":"536","author":"Rychter M.","year":"2019","unstructured":"Rychter M.; Milanowski B.; Grze\u015bkowiak B.F.; Jarek M.; Kempi\u0144ski M.; Coy E.L.; Borysiak S.; Baranowska-Korczyc A.; Lulek J.; Cilostazol-loaded electrospun three-dimensional systems for potential cardiovascular application: Effect of fibers hydrophilization on drug release, and cytocompatibility. J Colloid Interface Sci 2019,536,310-327","journal-title":"J Colloid Interface Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JAD-151078","volume":"51","author":"Manousopoulou A.","year":"2016","unstructured":"Manousopoulou A.; Saito S.; Yamamoto Y.; Al-Daghri N.M.; Ihara M.; Carare R.O.; Garbis S.D.; Hemisphere asymmetry of response to pharmacologic treatment in an Alzheimer\u2019s disease mouse model. J Alzheimers Dis 2016,51(2),333-338","journal-title":"J Alzheimers Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1161\/ATVBAHA.115.307011","volume":"36","author":"Sanada F.","year":"2016","unstructured":"Sanada F.; Kanbara Y.; Taniyama Y.; Otsu R.; Carracedo M.; Ikeda-Iwabu Y.; Muratsu J.; Sugimoto K.; Yamamoto K.; Rakugi H.; Morishita R.; Induction of angiogenesis by a type III phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-\u03b3 and camp pathways in vascular cells. Arterioscler Thromb Vasc Biol 2016,36(3),545-552","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3171\/2013.9.SPINE121136","volume":"20","author":"Yamamoto S.","year":"2014","unstructured":"Yamamoto S.; Kurokawa R.; Kim P.; Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model. J Neurosurg Spine 2014,20(1),93-101","journal-title":"J Neurosurg Spine"},{"key":"ref=57","first-page":"457","volume":"57","author":"de Donato G.","year":"2016","unstructured":"de Donato G.; Setacci F.; Galzerano G.; Mele M.; Ruzzi U.; Setacci C.; The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey. J Cardiovasc Surg (Torino) 2016,57(3),457-465","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17482940701263285","volume":"9","author":"Kibos A.","year":"2007","unstructured":"Kibos A.; Campeanu A.; Tintoiu I.; Pathophysiology of coronary artery in-stent restenosis. Acute Card Care 2007,9(2),111-119","journal-title":"Acute Card Care"},{"key":"ref=59","first-page":"540","volume":"42","author":"Okuda Y.","year":"1992","unstructured":"Okuda Y.; Mizutani M.; Ikegami T.; Ueno E.; Yamashita K.; Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy. Arzneimittelforschung 1992,42(4),540-542","journal-title":"Arzneimittelforschung"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.atherosclerosis.2011.08.033","volume":"219","author":"Liu Y.","year":"2011","unstructured":"Liu Y.; Wang T.; Yan J.; Jiagbogu N.; Heideman D.A.; Canfield A.E.; Alexander M.Y.; HGF\/c-Met signalling promotes Notch3 activation and human vascular smooth muscle cell osteogenic differentiation in vitro. Atherosclerosis 2011,219(2),440-447","journal-title":"Atherosclerosis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/jor.22967","volume":"33","author":"Herath S.C.","year":"2015","unstructured":"Herath S.C.; Lion T.; Klein M.; Stenger D.; Scheuer C.; Holstein J.H.; M\u00f6rsdorf P.; Rollmann M.F.; Pohlemann T.; Menger M.D.; Histing T.; Stimulation of angiogenesis by cilostazol accelerates fracture healing in mice. J Orthop Res 2015,33(12),1880-1887","journal-title":"J Orthop Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.HYP.35.1.237","volume":"35","author":"Hayashi S.","year":"2000","unstructured":"Hayashi S.; Morishita R.; Matsushita H.; Nakagami H.; Taniyama Y.; Nakamura T.; Aoki M.; Yamamoto K.; Higaki J.; Ogihara T.; Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000,35(1 Pt 2),237-243","journal-title":"Hypertension"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/ATVBAHA.107.145011","volume":"27","author":"Ohtsubo H.","year":"2007","unstructured":"Ohtsubo H.; Ichiki T.; Miyazaki R.; Inanaga K.; Imayama I.; Hashiguchi Y.; Sadoshima J.; Sunagawa K.; Inducible cAMP early repressor inhibits growth of vascular smooth muscle cell. Arterioscler Thromb Vasc Biol 2007,27(7),1549-1555","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/01.HYP.0000158263.64320.eb","volume":"45","author":"Kim M.J.","year":"2005","unstructured":"Kim M.J.; Park K.G.; Lee K.M.; Kim H.S.; Kim S.Y.; Kim C.S.; Lee S.L.; Chang Y.C.; Park J.Y.; Lee K.U.; Lee I.K.; Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005,45(4),552-556","journal-title":"Hypertension"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jacc.2004.06.066","volume":"44","author":"Inoue T.","year":"2004","unstructured":"Inoue T.; Uchida T.; Sakuma M.; Imoto Y.; Ozeki Y.; Ozaki Y.; Hikichi Y.; Node K.; Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004,44(7),1408-1414","journal-title":"J Am Coll Cardiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/sj.bjp.0701699","volume":"123","author":"Shiraishi Y.","year":"1998","unstructured":"Shiraishi Y.; Kanmura Y.; Itoh T.; Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998,123(5),869-878","journal-title":"Br J Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1038\/s41598-017-04082-0","volume":"7","author":"Kitamura A.","year":"2017","unstructured":"Kitamura A.; Manso Y.; Duncombe J.; Searcy J.; Koudelka J.; Binnie M.; Webster S.; Lennen R.; Jansen M.; Marshall I.; Ihara M.; Kalaria R.N.; Horsburgh K.; Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. Sci Rep 2017,7(1),4299","journal-title":"Sci Rep"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1177\/0091270002042012002","volume":"42","author":"Grouse J.R.","year":"2002","unstructured":"Grouse J.R.; Allan M.C.; Elam M.B.; Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication. J Clin Pharmacol 2002,42(12),1291-1298","journal-title":"J Clin Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jvs.2013.01.033","volume":"58","author":"Tanaka H.","year":"2013","unstructured":"Tanaka H.; Zaima N.; Ito H.; Hattori K.; Yamamoto N.; Konno H.; Setou M.; Unno N.; Cilostazol inhibits accumulation of triglycerides in a rat model of carotid artery ligation. J Vasc Surg 2013,58(5),1366-1374","journal-title":"J Vasc Surg"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1517\/14656566.2011.557359","volume":"12","author":"Rizzo M.","year":"2011","unstructured":"Rizzo M.; Corrado E.; Patti A.M.; Rini G.B.; Mikhailidis D.P.; Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011,12(4),647-655","journal-title":"Expert Opin Pharmacother"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0021-9150(99)00480-3","volume":"152","author":"Tani T.","year":"2000","unstructured":"Tani T.; Uehara K.; Sudo T.; Marukawa K.; Yasuda Y.; Kimura Y.; Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000,152(2),299-305","journal-title":"Atherosclerosis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1161\/01.ATV.18.12.1942","volume":"18","author":"Elam M.B.","year":"1998","unstructured":"Elam M.B.; Heckman J.; Crouse J.R.; Hunninghake D.B.; Herd J.A.; Davidson M.; Gordon I.L.; Bortey E.B.; Forbes W.P.; Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998,18(12),1942-1947","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0021-9150(01)00457-9","volume":"158","author":"Lee T.M.","year":"2001","unstructured":"Lee T.M.; Su S.F.; Hwang J.J.; Tseng C.D.; Chen M.F.; Lee Y.T.; Wang S.S.; Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis 2001,158(2),471-476","journal-title":"Atherosclerosis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1124\/jpet.103.052365","volume":"306","author":"Hong K.W.","year":"2003","unstructured":"Hong K.W.; Kim K.Y.; Shin H.K.; Lee J.H.; Choi J.M.; Kwak Y.G.; Kim C.D.; Lee W.S.; Rhim B.Y.; Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt\/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 2003,306(3),1182-1190","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1124\/jpet.104.077826","volume":"312","author":"Park S.Y.","year":"2005","unstructured":"Park S.Y.; Lee J.H.; Kim Y.K.; Kim C.D.; Rhim B.Y.; Lee W.S.; Hong K.W.; Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 2005,312(3),1241-1248","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2174\/138161206775474323","volume":"12","author":"Hong K.W.","year":"2006","unstructured":"Hong K.W.; Lee J.H.; Kima K.Y.; Park S.Y.; Lee W.S.; Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des 2006,12(5),565-573","journal-title":"Curr Pharm Des"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1161\/STROKEAHA.110.609834","volume":"42","author":"Oyama N.","year":"2011","unstructured":"Oyama N.; Yagita Y.; Kawamura M.; Sugiyama Y.; Terasaki Y.; Omura-Matsuoka E.; Sasaki T.; Kitagawa K.; Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 2011,42(9),2571-2577","journal-title":"Stroke"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203837","volume":"13","author":"El-Abhar H.","year":"2018","unstructured":"El-Abhar H.; Abd El Fattah M.A.; Wadie W.; El-Tanbouly D.M.; Cilostazol disrupts TLR-4, Akt\/GSK-3\u03b2\/CREB, and IL-6\/JAK-2\/STAT-3\/SOCS-3 crosstalk in a rat model of Huntington\u2019s disease. PLoS One 2018,13(9)","journal-title":"PLoS One"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.fct.2016.12.018","volume":"100","author":"Kangawa Y.","year":"2017","unstructured":"Kangawa Y.; Yoshida T.; Maruyama K.; Okamoto M.; Kihara T.; Nakamura M.; Ochiai M.; Hippo Y.; Hayashi S.M.; Shibutani M.; Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. Food Chem Toxicol 2017,100,103-114","journal-title":"Food Chem Toxicol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.intimp.2018.06.021","volume":"62","author":"Sakamoto T.","year":"2018","unstructured":"Sakamoto T.; Ohashi W.; Tomita K.; Hattori K.; Matsuda N.; Hattori Y.; Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-\u03baB from the Toll-like receptor signaling pathways. Int Immunopharmacol 2018,62,120-131","journal-title":"Int Immunopharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/2047487312452968","volume":"21","author":"Eraso L.H.","year":"2014","unstructured":"Eraso L.H.; Fukaya E.; Mohler E.R.; Xie D.; Sha D.; Berger J.S.; Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur J Prev Cardiol 2014,21(6),704-711","journal-title":"Eur J Prev Cardiol"},{"key":"ref=82","first-page":"294","volume":"55","author":"Carvounis C.P.","year":"2014","unstructured":"Carvounis C.P.; Nikas N.; Prevalence of peripheral arterial disease in subjects at moderate cardiovascular risk: Greek results of the PANDORA study. Hellenic J Cardiol 2014,55(4),294-304","journal-title":"Hellenic J Cardiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","volume":"96","author":"Murabito J.M.","year":"1997","unstructured":"Murabito J.M.; D\u2019Agostino R.B.; Silbershatz H.; Wilson W.F.; Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997,96(1),44-49","journal-title":"Circulation"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"Belch J.","year":"2008","unstructured":"Belch J.; MacCuish A.; Campbell I.; Cobbe S.; Taylor R.; Prescott R.; Lee R.; Bancroft J.; MacEwan S.; Shepherd J.; Macfarlane P.; Morris A.; Jung R.; Kelly C.; Connacher A.; Peden N.; Jamieson A.; Matthews D.; Leese G.; McKnight J.; O\u2019Brien I.; Semple C.; Petrie J.; Gordon D.; Pringle S.; MacWalter R.; The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008,337,a1840","journal-title":"BMJ"},{"key":"ref=85","first-page":"1149","volume":"35","author":"Kawamura K.","year":"1985","unstructured":"Kawamura K.; Watanabe K.; Kimura Y.; Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung 1985,35(7A),1149-1154","journal-title":"Arzneimittelforschung"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/archinte.159.17.2041","volume":"159","author":"Beebe H.G.","year":"1999","unstructured":"Beebe H.G.; Dawson D.L.; Cutler B.S.; Herd J.A.; Strandness D.E.; Bortey E.B.; Forbes W.P.; A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999,159(17),2041-2050","journal-title":"Arch Intern Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2011.09.048","volume":"220","author":"Geng D.F.","year":"2012","unstructured":"Geng D.F.; Deng J.; Jin D.M.; Wu W.; Wang J.F.; Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 2012,220(1),177-183","journal-title":"Atherosclerosis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12872-018-0822-4","volume":"18","author":"Real J.","year":"2018","unstructured":"Real J.; Serna M.C.; Giner-Soriano M.; For\u00e9s R.; Pera G.; Ribes E.; Alzamora M.; Marsal J.R.; Heras A.; Morros R.; Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. BMC Cardiovasc Disord 2018,18(1),85","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00415-012-6599-y","volume":"260","author":"Heo S.H.","year":"2013","unstructured":"Heo S.H.; Lee J.S.; Kim B.J.; Hwang K.J.; Kim J.H.; Chang D.I.; Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients. J Neurol 2013,260(1),122-130","journal-title":"J Neurol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1161\/CIRCULATIONAHA.109.892414","volume":"121","author":"Katakami N.","year":"2010","unstructured":"Katakami N.; Kim Y.S.; Kawamori R.; Yamasaki Y.; The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010,121(23),2584-2591","journal-title":"Circulation"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jvs.2009.08.040","volume":"51","author":"Takigawa T.","year":"2010","unstructured":"Takigawa T.; Matsumaru Y.; Hayakawa M.; Nemoto S.; Matsumura A.; Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010,51(1),51-56","journal-title":"J Vasc Surg"},{"key":"ref=92","first-page":"937","volume":"13","author":"Ahangarpour A.","year":"2014","unstructured":"Ahangarpour A.; Heidari H.; Mard S.A.; Hashemitabar M.; Khodadadi A.; Progesterone and cilostazol protect mice pancreatic islets from oxidative stress induced by hydrogen peroxide. Iran J Pharm Res 2014,13(3),937-944","journal-title":"Iran J Pharm Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12020-015-0545-6","volume":"49","author":"Liu J.S.","year":"2015","unstructured":"Liu J.S.; Chuang T.J.; Chen J.H.; Lee C.H.; Hsieh C.H.; Lin T.K.; Hsiao F.C.; Hung Y.J.; Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine 2015,49(3),703-710","journal-title":"Endocrine"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2014.08.034","volume":"73","author":"Kwon K.J.","year":"2015","unstructured":"Kwon K.J.; Lee E.J.; Kim M.K.; Kim S.Y.; Kim J.N.; Kim J.O.; Kim H.J.; Kim H.Y.; Han J.S.; Shin C.Y.; Han S.H.; Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia. Neurobiol Dis 2015,73,12-23","journal-title":"Neurobiol Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pbb.2015.05.006","volume":"135","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Kumar A.; Jaggi A.S.; Singh N.; Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia. Pharmacol Biochem Behav 2015,135,20-30","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12020-017-1279-4","volume":"56","author":"Asal N.J.","year":"2017","unstructured":"Asal N.J.; Wojciak K.A.; Effect of cilostazol in treating diabetes-associated microvascular complications. Endocrine 2017,56(2),240-244","journal-title":"Endocrine"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-013-0002-3","volume":"45","author":"Tang W.H.","year":"2014","unstructured":"Tang W.H.; Lin F.H.; Lee C.H.; Kuo F.C.; Hsieh C.H.; Hsiao F.C.; Hung Y.J.; Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014,45(2),293-301","journal-title":"Endocrine"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11239-014-1090-5","volume":"39","author":"Chen J.","year":"2015","unstructured":"Chen J.; Meng H.; Xu L.; Liu J.; Kong D.; Chen P.; Gong X.; Bai J.; Zou F.; Yang Z.; Li C.; Eikelboom J.W.; Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis 2015,39(1),23-34","journal-title":"J Thromb Thrombolysis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.jacc.2013.03.036","volume":"61","author":"Spiliopoulos S.","year":"2013","unstructured":"Spiliopoulos S.; Pastromas G.; Katsanos K.; Kitrou P.; Karnabatidis D.; Siablis D.; Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013,61(24),2428-2434","journal-title":"J Am Coll Cardiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000338054","volume":"47","author":"Fassa A.A.","year":"2012","unstructured":"Fassa A.A.; Urban P.; Stents and antiplatelet therapy. Adv Cardiol 2012,47,114-124","journal-title":"Adv Cardiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12872-015-0114-1","volume":"15","author":"Bundhun P.K.","year":"2015","unstructured":"Bundhun P.K.; Qin T.; Chen M.H.; Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2015,15,118","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000068","volume":"1","author":"Bangalore S.","year":"2014","unstructured":"Bangalore S.; Singh A.; Toklu B.; DiNicolantonio J.J.; Croce K.; Feit F.; Bhatt D.L.; Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart 2014,1(1)","journal-title":"Open Heart"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2010.10.035","volume":"57","author":"Lee S.W.","year":"2011","unstructured":"Lee S.W.; Park S.W.; Kim Y.H.; Yun S.C.; Park D.W.; Lee C.W.; Kang S.J.; Park S.J.; Lee J.H.; Choi S.W.; Seong I.W.; Lee N.H.; Cho Y.H.; Shin W.Y.; Lee S.J.; Lee S.W.; Hyon M.S.; Bang D.W.; Choi Y.J.; Kim H.S.; Lee B.K.; Lee K.; Park H.K.; Park C.B.; Lee S.G.; Kim M.K.; Park K.H.; Park W.J.; A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011,57(11),1264-1270","journal-title":"J Am Coll Cardiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40360-018-0224-3","volume":"19","author":"Huang F.","year":"2018","unstructured":"Huang F.; Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol 2018,19(1),31","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-018-0711-8","volume":"39","author":"Zhao S.","year":"2019","unstructured":"Zhao S.; Zhong Z.; Qi G.; Shi L.; Tian W.; Effects of cilostazol-based triple antiplatelet therapy versus dual antiplatelet therapy after coronary drug-eluting stent implantation: an updated meta-analysis of the randomized controlled trials. Clin Drug Investig 2019,39(1),1-13","journal-title":"Clin Drug Investig"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/CIRCINTERVENTIONS.109.880179","volume":"3","author":"Jeong Y.H.","year":"2010","unstructured":"Jeong Y.H.; Hwang J.Y.; Kim I.S.; Park Y.; Hwang S.J.; Lee S.W.; Kwak C.H.; Park S.W.; Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010,3(1),17-26","journal-title":"Circ Cardiovasc Interv"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","volume":"157","author":"Han Y.","year":"2009","unstructured":"Han Y.; Li Y.; Wang S.; Jing Q.; Wang Z.; Wang D.; Shu Q.; Tang X.; Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009,157(4),733-739","journal-title":"Am Heart J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.amjcard.2009.08.667","volume":"105","author":"Lee S.W.","year":"2010","unstructured":"Lee S.W.; Chun K.J.; Park S.W.; Kim H.S.; Kim Y.H.; Yun S.C.; Kim W.J.; Lee J.Y.; Park D.W.; Lee C.W.; Hong M.K.; Rhee K.S.; Chae J.K.; Ko J.K.; Park J.H.; Lee J.H.; Choi S.W.; Jeong J.O.; Seong I.W.; Jon S.; Cho Y.H.; Lee N.H.; Kim J.H.; Park S.J.; Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010,105(2),168-173","journal-title":"Am J Cardiol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.amjcard.2013.06.010","volume":"112","author":"Lee S.W.","year":"2013","unstructured":"Lee S.W.; Ahn J.M.; Han S.; Park G.M.; Cho Y.R.; Lee W.S.; Jang J.Y.; Kwon C.H.; Lee J.Y.; Kim W.J.; Kang S.J.; Kim Y.H.; Lee C.W.; Kim J.J.; Park S.W.; Park S.J.; Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). Am J Cardiol 2013,112(9),1328-1334","journal-title":"Am J Cardiol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1536\/ihj.16-332","volume":"58","author":"Suh J.W.","year":"2017","unstructured":"Suh J.W.; Lee S.P.; Park K.; Kang H.J.; Koo B.K.; Cho Y.S.; Youn T.J.; Chae I.H.; Choi D.J.; Rha S.W.; Bae J.H.; Kwon T.G.; Bae J.W.; Cho M.C.; Kim H.S.; the effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemi complication after drug-eluting StenT implantation) Trial. Int Heart J 2017,58(6),853-860","journal-title":"Int Heart J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(13)70255-2","volume":"13","author":"Hankey G.J.","year":"2014","unstructured":"Hankey G.J.; Secondary stroke prevention. Lancet Neurol 2014,13(2),178-194","journal-title":"Lancet Neurol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/ane.12111","volume":"128","author":"Mijajlovic M.D.","year":"2013","unstructured":"Mijajlovic M.D.; Shulga O.; Bloch S.; Covickovic-Sternic N.; Aleksic V.; Bornstein N.M.; Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurol Scand 2013,128(4),213-219","journal-title":"Acta Neurol Scand"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.mce.2013.07.011","volume":"381","author":"Biscetti F.","year":"2013","unstructured":"Biscetti F.; Pecorini G.; Arena V.; Stigliano E.; Angelini F.; Ghirlanda G.; Ferraccioli G.; Flex A.; Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPAR\u03b3. Mol Cell Endocrinol 2013,381(1-2),80-87","journal-title":"Mol Cell Endocrinol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.11.023","volume":"23","author":"Nakase T.","year":"2014","unstructured":"Nakase T.; Sasaki M.; Suzuki A.; The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. J Stroke Cerebrovasc Dis 2014,23(6),1409-1415","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.thromres.2018.10.003","volume":"172","author":"Ikeda Y.","year":"2018","unstructured":"Ikeda Y.; Yamanouchi J.; Kumon Y.; Yasukawa M.; Hato T.; Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction. Thromb Res 2018,172,14-20","journal-title":"Thromb Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"832","DOI":"10.5692\/clinicalneurol.50.832","volume":"50","author":"Uchiyama S.","year":"2010","unstructured":"Uchiyama S.; Results of the cilostazol stroke prevention study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. Rinsho Shinkeigaku 2010,50(11),832-834","journal-title":"Rinsho Shinkeigaku"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/jscd.2000.7216","volume":"9","author":"Gotoh F.","year":"2000","unstructured":"Gotoh F.; Tohgi H.; Hirai S.; Terashi A.; Fukuuchi Y.; Otomo E.; Shinohara Y.; Itoh E.; Matsuda T.; Sawada T.; Yamaguchi T.; Nishimaru K.; Ohashi Y.; Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000,9(4),147-157","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000135654","volume":"26","author":"Shinohara Y.","year":"2008","unstructured":"Shinohara Y.; Gotoh F.; Tohgi H.; Hirai S.; Terashi A.; Fukuuchi Y.; Otomo E.; Itoh E.; Matsuda T.; Sawada T.; Yamaguchi T.; Nishimaru K.; Ohashi Y.; Antiplatelet cilostazol is beneficial in diabetic and\/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008,26(1),63-70","journal-title":"Cerebrovasc Dis"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","volume":"9","author":"Shinohara Y.","year":"2010","unstructured":"Shinohara Y.; Katayama Y.; Uchiyama S.; Yamaguchi T.; Handa S.; Matsuoka K.; Ohashi Y.; Tanahashi N.; Yamamoto H.; Genka C.; Kitagawa Y.; Kusuoka H.; Nishimaru K.; Tsushima M.; Koretsune Y.; Sawada T.; Hamada C.; Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010,9(10),959-968","journal-title":"Lancet Neurol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2011.09.038","volume":"313","author":"Nakamura T.","year":"2012","unstructured":"Nakamura T.; Tsuruta S.; Uchiyama S.; Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. J Neurol Sci 2012,313(1-2),22-26","journal-title":"J Neurol Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.12.002","volume":"24","author":"Tan L.","year":"2015","unstructured":"Tan L.; Margaret B.; Zhang J.H.; Hu R.; Yin Y.; Cao L.; Feng H.; Zhang Y.; Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis 2015,24(5),930-938","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.amjcard.2013.05.067","volume":"112","author":"Dinicolantonio J.J.","year":"2013","unstructured":"Dinicolantonio J.J.; Lavie C.J.; Fares H.; Menezes A.R.; O\u2019Keefe J.H.; Bangalore S.; Messerli F.H.; Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013,112(8),1230-1234","journal-title":"Am J Cardiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000327036","volume":"32","author":"Lee Y.S.","year":"2011","unstructured":"Lee Y.S.; Bae H.J.; Kang D.W.; Lee S.H.; Yu K.; Park J.M.; Cho Y.J.; Hong K.S.; Kim D.E.; Kwon S.U.; Lee K.B.; Rha J.H.; Koo J.; Han M.G.; Lee S.J.; Lee J.H.; Jung S.W.; Lee B.C.; Kim J.S.; Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011,32(1),65-71","journal-title":"Cerebrovasc Dis"},{"key":"ref=124","author":"Kamal A.K.","year":"2011","unstructured":"Kamal A.K.; Naqvi I.; Husain M.R.; Khealani B.A.; Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011(1)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.027","volume":"27","author":"Saber H.","year":"2018","unstructured":"Saber H.; Desai A.; Palla M.; Mohamed W.; Seraji-Bozorgzad N.; Ibrahim M.; Efficacy of cilostazol in prevention of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a meta-analysis. J Stroke Cerebrovasc Dis 2018,27(11),2979-2985","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000365840","volume":"38","author":"Han S.W.","year":"2014","unstructured":"Han S.W.; Song T.J.; Bushnell C.D.; Lee S.S.; Kim S.H.; Lee J.H.; Kim G.S.; Kim O.J.; Koh I.S.; Lee J.Y.; Suk S.H.; Lee S.I.; Nam H.S.; Kim W.J.; Lee K.Y.; Park J.H.; Kim J.Y.; Park J.H.; Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) study. Cerebrovasc Dis 2014,38(3),197-203","journal-title":"Cerebrovasc Dis"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"914","DOI":"10.5692\/clinicalneurol.50.914","volume":"50","author":"Yamamoto Y.","year":"2010","unstructured":"Yamamoto Y.; Ohara T.; Nagakane Y.; Tanaka E.; Morii F.; Koizumi T.; Concept of branch atheromatous disease (BAD) and its clinical significance. Rinsho Shinkeigaku 2010,50,914-917","journal-title":"Rinsho Shinkeigaku"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/hr.2009.211","volume":"33","author":"Sakurada M.","year":"2010","unstructured":"Sakurada M.; Yoshimoto T.; Sekizawa N.; Hirono Y.; Suzuki N.; Hirata Y.; Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. Hypertens Res 2010,33(3),229-235","journal-title":"Hypertens Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jnr.23327","volume":"92","author":"Omote Y.","year":"2014","unstructured":"Omote Y.; Deguchi K.; Kono S.; Liu N.; Liu W.; Kurata T.; Yamashita T.; Ikeda Y.; Abe K.; Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. J Neurosci Res 2014,92(3),369-374","journal-title":"J Neurosci Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","volume":"36","author":"Kwon S.U.","year":"2005","unstructured":"Kwon S.U.; Cho Y.J.; Koo J.S.; Bae H.J.; Lee Y.S.; Hong K.S.; Lee J.H.; Kim J.S.; Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005,36(4),782-786","journal-title":"Stroke"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1054\/JCPT.2000.8696","volume":"5","author":"Toyonaga S.","year":"2000","unstructured":"Toyonaga S.; Nakatsu T.; Murakami T.; Kusachi S.; Mashima K.; Tominaga Y.; Yamane S.; Uesugi T.; Kanai H.; Tsuji T.; Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. J Cardiovasc Pharmacol Ther 2000,5(3),183-191","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/147323000403200513","volume":"32","author":"Moriya I.","year":"2004","unstructured":"Moriya I.; Takahashi T.; Nomura Y.; Kawaura K.; Kusaka K.; Yamakawa J.; Fujioka N.; Okubo S.; Itoh T.; Kanda T.; Chronotropic effect of the antithrombotic agent cilostazol in a patient with sick sinus syndrome and syncope. J Int Med Res 2004,32(5),549-551","journal-title":"J Int Med Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2170\/jjphysiol.50.405","volume":"50","author":"Mizuo J.","year":"2000","unstructured":"Mizuo J.; Nakatsu T.; Murakami T.; Kusachi S.; Tominaga Y.; Mashima K.; Uesugi T.; Ueda H.; Suezawa C.; Tsuji T.; Exponential hyperbolic sine function fitting of heart rate response to constant load exercise. Jpn J Physiol 2000,50(4),405-412","journal-title":"Jpn J Physiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0928-8244(01)00245-0","volume":"31","author":"de la Pe\u00f1a-Moctezuma A.","year":"2001","unstructured":"de la Pe\u00f1a-Moctezuma A.; Bulach D.M.; Adler B.; Genetic differences among the LPS biosynthetic loci of serovars of Leptospira interrogans and Leptospira borgpetersenii. FEMS Immunol Med Microbiol 2001,31(1),73-81","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.yjmcc.2006.10.004","volume":"42","author":"Du Y.M.","year":"2007","unstructured":"Du Y.M.; Nathan R.D.; Ionic basis of ischemia-induced bradycardia in the rabbit sinoatrial node. J Mol Cell Cardiol 2007,42(2),315-325","journal-title":"J Mol Cell Cardiol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41479-018-0046-5","volume":"10","author":"Nakashima H.","year":"2018","unstructured":"Nakashima H.; Watanabe K.; Umegaki H.; Suzuki Y.; Kuzuya M.; Cilostazol for the prevention of pneumonia: a systematic review. Pneumonia (Nathan) 2018,10,3","journal-title":"Pneumonia (Nathan)"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/ATVBAHA.117.309707","volume":"38","author":"Umebayashi R.","year":"2018","unstructured":"Umebayashi R.; Uchida H.A.; Kakio Y.; Subramanian V.; Daugherty A.; Wada J.; Cilostazol attenuates angiotensin ii-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2018,38(4),903-912","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=138","author":"Iqbal A.M.","year":"2019","unstructured":"Iqbal A.M.; Hai, O. Antiplatelet Medications. StatPearls Publishing LLC: Treasure Island 2019"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102417719753","volume":"38","author":"Khan S.","year":"2018","unstructured":"Khan S.; Deen M.; Hougaard A.; Amin F.M.; Ashina M.; Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. Cephalalgia 2018,38(5),892-903","journal-title":"Cephalalgia"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.ijcard.2012.06.010","volume":"167","author":"Sakurai R.","year":"2013","unstructured":"Sakurai R.; Koo B.K.; Kaneda H.; Bonneau H.N.; Nagai R.; Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 2013,167(5),2250-2258","journal-title":"Int J Cardiol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0333102417693833","volume":"38","author":"Christensen S.L.","year":"2018","unstructured":"Christensen S.L.; Petersen S.; S\u00f8rensen D.B.; Olesen J.; Jansen-Olesen I.; Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats. Cephalalgia 2018,38(3),452-465","journal-title":"Cephalalgia"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2169\/internalmedicine.50.4384","volume":"50","author":"Nishiyama K.","year":"2011","unstructured":"Nishiyama K.; Seyama H.; Okano H.; Yamada S.; Kurita H.; Chiba A.; Yamaguchi Y.; Shiokawa Y.; Escalation regimen of cilostazol for acute brain infarction. Intern Med 2011,50(15),1559-1563","journal-title":"Intern Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1160\/TH05-12-0802","volume":"96","author":"Smit J.J.","year":"2006","unstructured":"Smit J.J.; van \u2019t Hof A.W.; de Boer M.J.; Hoorntje J.C.; Dambrink J.H.; Gosselink A.T.; Ottervanger J.P.; Kolkman J.J.; Suryapranata H.; Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 2006,96(2),190-195","journal-title":"Thromb Haemost"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.amjcard.2013.08.008","volume":"112","author":"Lee S.W.","year":"2013","unstructured":"Lee S.W.; Lee J.Y.; Ahn J.M.; Park D.W.; Han S.; Park Y.K.; Lee W.S.; Jang J.Y.; Kwon C.H.; Park G.M.; Cho Y.R.; Kim W.J.; Kang S.J.; Kim Y.H.; Lee C.W.; Kim J.J.; Park S.W.; Park S.J.; Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Am J Cardiol 2013,112,1738-1744","journal-title":"Am J Cardiol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00380-010-0093-1","volume":"26","author":"Ahn C.M.","year":"2011","unstructured":"Ahn C.M.; Hong S.J.; Park J.H.; Kim J.S.; Lim D.S.; Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2011,26(5),502-510","journal-title":"Heart Vessels"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000338812","volume":"122","author":"Geng D.F.","year":"2012","unstructured":"Geng D.F.; Liu M.; Jin D.M.; Wu W.; Deng J.; Wang J.F.; Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology 2012,122(3),148-157","journal-title":"Cardiology"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1042\/bj1870829","volume":"187","author":"Chou K.C.","year":"1980","unstructured":"Chou K.C.; Fors\u00e9n S.; Graphical rules for enzyme-catalysed rate laws. Biochem J 1980,187(3),829-835","journal-title":"Biochem J"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0301-4622(80)80002-0","volume":"12","author":"Chou K.C.","year":"1980","unstructured":"Chou K.C.; Fors\u00e9n S.; Diffusion-controlled effects in reversible enzymatic fast reaction systems--critical spherical shell and proximity rate constant. Biophys Chem 1980,12(3-4),255-263","journal-title":"Biophys Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0301-4622(80)80003-2","volume":"12","author":"Chou K.C.","year":"1980","unstructured":"Chou K.C.; Li T.T.; Fors\u00e9n S.; The critical spherical shell in enzymatic fast reaction systems. Biophys Chem 1980,12(3-4),265-269","journal-title":"Biophys Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0006-3495(84)84234-4","volume":"45","author":"Chou K.C.","year":"1984","unstructured":"Chou K.C.; Biological functions of low-frequency vibrations (phonons). III. Helical structures and microenvironment. Biophys J 1984,45(5),881-889","journal-title":"Biophys J"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0301-4622(84)80005-8","volume":"20","author":"Chou K.C.","year":"1984","unstructured":"Chou K.C.; The biological functions of low-frequency vibrations (phonons). 4. Resonance effects and allosteric transition. Biophys Chem 1984,20(1-2),61-71","journal-title":"Biophys Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/bj2210027","volume":"221","author":"Chou K.C.","year":"1984","unstructured":"Chou K.C.; Low-frequency vibrations of DNA molecules. Biochem J 1984,221(1),27-31","journal-title":"Biochem J"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0006-3495(85)83782-6","volume":"48","author":"Chou K.C.","year":"1985","unstructured":"Chou K.C.; Low-frequency motions in protein molecules. Beta-sheet and beta-barrel. Biophys J 1985,48(2),289-297","journal-title":"Biophys J"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0301-4622(86)87001-6","volume":"25","author":"Chou K.C.","year":"1986","unstructured":"Chou K.C.; Origin of low-frequency motions in biological macromolecules. A view of recent progress in the quasi-continuity model. Biophys Chem 1986,25(2),105-116","journal-title":"Biophys Chem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0301-4622(88)85002-6","volume":"30","author":"Chou K.C.","year":"1988","unstructured":"Chou K.C.; Low-frequency collective motion in biomacromolecules and its biological functions. Biophys Chem 1988,30(1),3-48","journal-title":"Biophys Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/0968-0004(89)90026-1","volume":"14","author":"Chou K.C.","year":"1989","unstructured":"Chou K.C.; Low-frequency resonance and cooperativity of hemoglobin. Trends Biochem Sci 1989,14(6),212-213","journal-title":"Trends Biochem Sci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0006-3495(89)82676-1","volume":"56","author":"Chou K.C.","year":"1989","unstructured":"Chou K.C.; Maggiora G.M.; Mao B.; Quasi-continuum models of twist-like and accordion-like low-frequency motions in DNA. Biophys J 1989,56(2),295-305","journal-title":"Biophys J"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"12074","DOI":"10.1016\/S0021-9258(18)80175-2","volume":"264","author":"Chou K.C.","year":"1989","unstructured":"Chou K.C.; Graphic rules in steady and non-steady state enzyme kinetics. J Biol Chem 1989,264(20),12074-12079","journal-title":"J Biol Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0301-4622(90)80056-D","volume":"35","author":"Chou K.C.","year":"1990","unstructured":"Chou K.C.; Applications of graph theory to enzyme kinetics and protein folding kinetics. Steady and non-steady-state systems. Biophys Chem 1990,35(1),1-24","journal-title":"Biophys Chem"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/S0021-9258(18)53227-0","volume":"268","author":"Althaus I.W.","year":"1993","unstructured":"Althaus I.W.; Chou J.J.; Gonzales A.J.; Deibel M.R.; Chou K.C.; Kezdy F.J.; Romero D.L.; Aristoff P.A.; Tarpley W.G.; Reusser F.; Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem 1993,268(9),6119-6124","journal-title":"J Biol Chem"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"14875","DOI":"10.1016\/S0021-9258(18)82414-0","volume":"268","author":"Althaus I.W.","year":"1993","unstructured":"Althaus I.W.; Gonzales A.J.; Chou J.J.; Romero D.L.; Deibel M.R.; Chou K.C.; Kezdy F.J.; Resnick L.; Busso M.E.; So A.G.; The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase. J Biol Chem 1993,268(20),14875-14880","journal-title":"J Biol Chem"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/0006-2952(94)90077-9","volume":"47","author":"Althaus I.W.","year":"1994","unstructured":"Althaus I.W.; Chou J.J.; Gonzales A.J.; Deibel M.R.; Chou K.C.; Kezdy F.J.; Romero D.L.; Thomas R.C.; Aristoff P.A.; Tarpley W.G.; Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994,47(11),2017-2028","journal-title":"Biochem Pharmacol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF01992044","volume":"50","author":"Althaus I.W.","year":"1994","unstructured":"Althaus I.W.; Chou J.J.; Gonzales A.J.; LeMay R.J.; Deibel M.R.; Chou K.C.; Kezdy F.J.; Romero D.L.; Thomas R.C.; Aristoff P.A.; Steady-state kinetic studies with the polysulfonate U-9843, an HIV reverse transcriptase inhibitor. Experientia 1994,50(1),23-28","journal-title":"Experientia"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1006\/abio.1994.1405","volume":"221","author":"Chou K.C.","year":"1994","unstructured":"Chou K.C.; K\u00e9zdy F.J.; Reusser F.; Kinetics of processive nucleic acid polymerases and nucleases. Anal Biochem 1994,221(2),217-230","journal-title":"Anal Biochem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/bip.360340114","volume":"34","author":"Chou K.C.","year":"1994","unstructured":"Chou K.C.; Zhang C.T.; Maggiora G.M.; Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth. Biopolymers 1994,34(1),143-153","journal-title":"Biopolymers"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/0006-2952(95)02390-9","volume":"51","author":"Althaus I.W.","year":"1996","unstructured":"Althaus I.W.; Chou K.C.; Lemay R.J.; Franks K.M.; Deibel M.R.; Kezdy F.J.; Resnick L.; Busso M.E.; So A.G.; Downey K.M.; Romero D.L.; Thomas R.C.; Aristoff P.A.; Tarpley W.G.; Reusser F.; The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem Pharmacol 1996,51(6),743-750","journal-title":"Biochem Pharmacol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.bbrc.2009.10.014","volume":"390","author":"Wang J.F.","year":"2009","unstructured":"Wang J.F.; Chou K.C.; Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun 2009,390(3),608-612","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018587","volume":"6","author":"Lian P.","year":"2011","unstructured":"Lian P.; Wei D.Q.; Wang J.F.; Chou K.C.; An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes. PLoS One 2011,6(4)","journal-title":"PLoS One"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/157340611794072698","volume":"7","author":"Liao Q.H.","year":"2011","unstructured":"Liao Q.H.; Gao Q.Z.; Wei J.; Chou K.C.; Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Med Chem 2011,7(1),24-31","journal-title":"Med Chem"},{"key":"ref=170","author":"Cheng X.","year":"2017","unstructured":"Cheng X.; Xiao X.; Chou, K.C. pLoc-mGneg: Predict subcellular localization of Gram-negative bacterial proteins by deep gene ontology learning via general PseAAC. Genomics S0888- 7543(17), 30102-30107.2017","journal-title":"Genomics"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.gene.2017.07.036","volume":"628","author":"Cheng X.","year":"2017","unstructured":"Cheng X.; Xiao X.; Chou K.C.; pLoc-mVirus: Predict subcellular localization of multi-location virus proteins via incorporating the optimal GO information into general PseAAC. Gene 2017,628,315-321","journal-title":"Gene"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.2174\/1381612824666181119145030","volume":"24","author":"Cheng X.","year":"2018","unstructured":"Cheng X.; Xiao X.; Chou K.C.; pLoc_bal-mPlant: Predict subcellular localization of plant proteins by general PseAAC and balancing training dataset. Curr Pharm Des 2018,24(34),4013-4022","journal-title":"Curr Pharm Des"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jtbi.2018.09.005","volume":"458","author":"Cheng X.","year":"2018","unstructured":"Cheng X.; Xiao X.; Chou K.C.; pLoc_bal-mGneg: Predict subcellular localization of Gram-negative bacterial proteins by quasi-balancing training dataset and general PseAAC. J Theor Biol 2018,458,92-102","journal-title":"J Theor Biol"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/bioinformatics\/btx711","volume":"34","author":"Cheng X.","year":"2018","unstructured":"Cheng X.; Xiao X.; Chou K.C.; pLoc-mHum: predict subcellular localization of multi-location human proteins via general PseAAC to winnow out the crucial GO information. Bioinformatics 2018,34(9),1448-1456","journal-title":"Bioinformatics"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ygeno.2017.08.005","volume":"110","author":"Cheng X.","year":"2018","unstructured":"Cheng X.; Xiao X.; Chou K.C.; pLoc-mEuk: Predict subcellular localization of multi-label eukaryotic proteins by extracting the key GO information into general PseAAC. Genomics 2018,110(1),50-58","journal-title":"Genomics"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1093\/bioinformatics\/btx476","volume":"33","author":"Cheng X.","year":"2017","unstructured":"Cheng X.; Zhao S.G.; Lin W.Z.; Xiao X.; Chou K.C.; pLoc-mAnimal: predict subcellular localization of animal proteins with both single and multiple sites. Bioinformatics 2017,33(22),3524-3531","journal-title":"Bioinformatics"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/bioinformatics\/btx387","volume":"33","author":"Cheng X.","year":"2017","unstructured":"Cheng X.; Zhao S.G.; Xiao X.; Chou K.C.; iATC-mISF: a multi-label classifier for predicting the classes of anatomical therapeutic chemicals. Bioinformatics 2017,33(3),341-346","journal-title":"Bioinformatics"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygeno.2017.10.008","volume":"110","author":"Qiu W.R.","year":"2018","unstructured":"Qiu W.R.; Sun B.Q.; Xiao X.; Xu Z.C.; Jia J.H.; Chou K.C.; iKcr-PseEns: Identify lysine crotonylation sites in histone proteins with pseudo components and ensemble classifier. Genomics 2018,110(5),239-246","journal-title":"Genomics"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.18632\/oncotarget.13758","volume":"8","author":"Chen W.","year":"2017","unstructured":"Chen W.; Feng P.; Yang H.; Ding H.; Lin H.; Chou K.C.; iRNA-AI: identifying the adenosine to inosine editing sites in RNA sequences. Oncotarget 2017,8(3),4208-4217","journal-title":"Oncotarget"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.omtn.2017.04.008","volume":"7","author":"Liu B.","year":"2017","unstructured":"Liu B.; Yang F.; Chou K.C.; 2L-piRNA: A Two-Layer Ensemble Classifier for Identifying Piwi-Interacting RNAs and Their Function. Mol Ther Nucleic Acids 2017,7,267-277","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/bioinformatics\/btw539","volume":"33","author":"Liu B.","year":"2017","unstructured":"Liu B.; Wang S.; Long R.; Chou K.C.; iRSpot-EL: identify recombination spots with an ensemble learning approach. Bioinformatics 2017,33(1),35-41","journal-title":"Bioinformatics"},{"key":"ref=182","doi-asserted-by":"publisher","DOI":"10.1002\/minf.201600010","volume":"36","author":"Qiu W.R.","year":"2017","unstructured":"Qiu W.R.; Sun B.Q.; Xiao X.; Xu D.; Chou, K.C. iPhos-PseEvo: identifying human phosphorylated proteins by incorporating evolutionary information into general PseAAC via grey system theory. Mol Inform 2017,36(5-6)","journal-title":"Mol Inform"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ygeno.2018.08.007","volume":"111","author":"Chou K.C.","year":"2018","unstructured":"Chou K.C.; Cheng X.; Xiao, X. pLoc_bal-mHum: Predict subcellular localization of human proteins by PseAAC and quasi-balancing training dataset. Genomics 2018,111(6),1274-1282","journal-title":"Genomics"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ygeno.2018.05.017","volume":"111","author":"Xiao X.","year":"2019","unstructured":"Xiao X.; Cheng X.; Chen G.; Mao Q.; Chou K.C.; pLoc_bal-mGpos: Predict subcellular localization of Gram-positive bacterial proteins by quasi-balancing training dataset and PseAAC. Genomics 2019,111(4),886-892","journal-title":"Genomics"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1573406415666181217114710","volume":"15","author":"Xiao X.","year":"2019","unstructured":"Xiao X.; Cheng X.; Chen G.; Mao Q.; Chou K.C.; pLoc_bal-mVirus: predict subcellular localization of multi-label virus proteins by chou\u2019s General PseAAC and IHTS treatment to balance training dataset. Med Chem 2019,15(5),496-509","journal-title":"Med Chem"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/bioinformatics\/bty628","volume":"35","author":"Cheng X.","year":"2019","unstructured":"Cheng X.; Lin W.Z.; Xiao X.; Chou K.C.; pLoc_bal-mAnimal: predict subcellular localization of animal proteins by balancing training dataset and PseAAC. Bioinformatics 2019,35(3),398-406","journal-title":"Bioinformatics"},{"key":"ref=187","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190507082559","author":"Chou K.C.","year":"2019","unstructured":"Chou K.C.; Advance in predicting subcellular localization of multi-label proteins and its implication for developing multi-target drugs. Curr Med Chem [Epub ahead of Print2019","journal-title":"Curr Med Chem"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2174\/1568026617666170414145508","volume":"17","author":"Chou K.C.","year":"2017","unstructured":"Chou K.C.; An unprecedented revolution in medicinal chemistry driven by the progress of biological science. Curr Top Med Chem 2017,17(21),2337-2358","journal-title":"Curr Top Med Chem"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T06:04:40Z","timestamp":1612591480000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176927\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":188,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2020,1,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666191122123855","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}